Karyopharm Therapeutics Inc. and its subsidiary filed voluntary petitions for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the Southern District of Texas. The company entered into a Restructuring Support Agreement with 100% of its funded debt holders and Ayrmid Ltd., which will serve as a stalking horse bidder for a merger with the reorganized company. The company will continue operations as a debtor-in-possession while seeking a court-supervised sale or reorganization to maximize stakeholder value.
Karyopharm Therapeutics has filed for voluntary Chapter 11 bankruptcy protection to implement a Restructuring Support Agreement and a planned merger with Ayrmid Ltd. The company secured $55 million in debtor-in-possession (DIP) financing to maintain operations during the court-supervised sale process. Existing equity holders are warned that their common and preferred stock will likely have no value and experience a complete loss.
Karyopharm Therapeutics has extended its existing Forbearance Agreement and Limited Waiver to Indentures from October 22, 2026, to November 1, 2026. This extension provides the company additional time to address its debt obligations while lenders agree to refrain from exercising certain rights or remedies during this period.
Karyopharm Therapeutics Inc. has extended its existing forbearance period under a Forbearance Agreement and Limited Waiver to Indentures. The expiration date of the forbearance period was moved from October 15, 2026, to October 22, 2026, providing the company additional time to address its debt obligations.
Karyopharm Therapeutics issued 20,000 shares of a newly created Series A Convertible Perpetual Preferred Stock to satisfy $20.0 million in fees owed under a forbearance agreement with its lenders. The preferred stock is convertible into common stock at $1.62 per share, though initial conversions are capped at 19.99% of outstanding shares pending stockholder approval.